
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2007

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission file number 1-5975

HUMANA INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

61-0647538
(I.R.S. Employer
Identification Number)

**500 West Main Street
Louisville, Kentucky 40202**
(Address of principal executive offices, including zip code)

(502) 580-1000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act: (Check one):

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of the latest practicable date.

Class of Common Stock

\$0.16 ²/₃ par value

Outstanding at June 30, 2007

168,562,724 shares

[Table of Contents](#)

Humana Inc.
FORM 10-Q
JUNE 30, 2007

INDEX

| | <u>Page</u> |
|---|-------------|
| <u>Part I: Financial Information</u> | |
| Item 1. Financial Statements | |
| Condensed Consolidated Balance Sheets at June 30, 2007 and December 31, 2006 | 3 |
| Condensed Consolidated Statements of Income for the three and six months ended June 30, 2007 and 2006 | 4 |
| Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2007 and 2006 | 5 |
| Notes to Condensed Consolidated Financial Statements | 6 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 13 |
| Item 3. Quantitative and Qualitative Disclosures about Market Risk | 24 |
| Item 4. Controls and Procedures | 24 |
| <u>Part II: Other Information</u> | |
| Item 1. Legal Proceedings | 25 |
| Item 1A. Risk Factors | 25 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 26 |
| Item 3. Defaults Upon Senior Securities | 26 |
| Item 4. Submission of Matters to a Vote of Security Holders | 26 |
| Item 5. Other Information | 26 |
| Item 6. Exhibits | 26 |
| Signatures and Certifications | 27 |

Humana Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

| | June 30, 2007 | December 31, 2006 |
|--|--------------------------------------|----------------------|
| | (in thousands, except share amounts) | |
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 3,720,769 | \$ 1,740,304 |
| Investment securities | 3,323,536 | 3,192,273 |
| Receivables, less allowance for doubtful accounts of \$69,327 in 2007 and \$45,589 in 2006: | | |
| Premiums | 685,479 | 667,657 |
| Administrative services fees | 12,074 | 13,284 |
| Securities lending collateral | 1,346,065 | 627,990 |
| Other current assets | 1,318,003 | 1,091,465 |
| Total current assets | 10,405,926 | 7,332,973 |
| Property and equipment, net | 569,412 | 545,004 |
| Other assets: | | |
| Long-term investment securities | 400,775 | 414,877 |
| Goodwill | 1,330,585 | 1,310,631 |
| Other long-term assets | 628,267 | 524,011 |
| Total other assets | 2,359,627 | 2,249,519 |
| Total assets | <u>\$ 13,334,965</u> | <u>\$ 10,127,496</u> |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Current liabilities: | | |
| Medical and other expenses payable | \$ 2,954,146 | \$ 2,488,261 |
| Trade accounts payable and accrued expenses | 2,084,463 | 1,626,658 |
| Book overdraft | 289,646 | 293,605 |
| Securities lending payable | 1,346,065 | 627,990 |
| Unearned revenues | 1,355,017 | 155,298 |
| Total current liabilities | 8,029,337 | 5,191,812 |
| Long-term debt | 1,189,570 | 1,269,100 |
| Other long-term liabilities | 740,560 | 612,698 |
| Total liabilities | <u>9,959,467</u> | <u>7,073,610</u> |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Preferred stock, \$1 par; 10,000,000 shares authorized; none issued | — | — |
| Common stock, \$0.16 2/3 par; 300,000,000 shares authorized; 185,002,041 shares issued at June 30, 2007 and 182,947,691 shares issued at December 31, 2006 | 30,833 | 30,491 |
| Capital in excess of par value | 1,422,370 | 1,357,077 |
| Retained earnings | 2,197,185 | 1,909,098 |
| Accumulated other comprehensive loss | (38,112) | (13,205) |
| Treasury stock, at cost, 16,439,317 shares at June 30, 2007 and 16,314,151 shares at December 31, 2006 | <u>(236,778)</u> | <u>(229,575)</u> |
| Total stockholders' equity | 3,375,498 | 3,053,886 |
| Total liabilities and stockholders' equity | \$ 13,334,965 | \$ 10,127,496 |

See accompanying notes to condensed consolidated financial statements.

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

| | Three months ended June 30, | | Six months ended June 30, | |
|-------------------------------------|--|------------------|------------------------------|-------------------|
| | 2007 | 2006 | 2007 | 2006 |
| | (in thousands, except per share results) | | | |
| Revenues: | | | | |
| Premiums | \$6,223,250 | \$5,264,475 | \$12,227,813 | \$ 9,785,961 |
| Administrative services fees | 97,093 | 83,711 | 192,957 | 162,389 |
| Investment income | 72,052 | 50,567 | 145,579 | 149,469 |
| Other revenue | 34,402 | 8,416 | 65,261 | 13,715 |
| Total revenues | <u>6,426,797</u> | <u>5,407,169</u> | <u>12,631,610</u> | <u>10,111,534</u> |
| Operating expenses: | | | | |
| Medical | 5,190,418 | 4,479,501 | 10,404,418 | 8,263,427 |
| Selling, general and administrative | 826,459 | 733,863 | 1,647,069 | 1,474,749 |
| Depreciation and amortization | 54,264 | 36,596 | 94,328 | 71,502 |
| Total operating expenses | <u>6,071,141</u> | <u>5,249,960</u> | <u>12,145,815</u> | <u>9,809,678</u> |
| Income from operations | 355,656 | 157,209 | 485,795 | 301,856 |
| Interest expense | 16,066 | 16,887 | 33,984 | 30,326 |
| Income before income taxes | 339,590 | 140,322 | 451,811 | 271,530 |
| Provision for income taxes | 122,744 | 50,833 | 163,724 | 98,326 |
| Net income | <u>\$ 216,846</u> | <u>\$ 89,489</u> | <u>\$ 288,087</u> | <u>\$ 173,204</u> |
| Basic earnings per common share | <u>\$ 1.30</u> | <u>\$ 0.55</u> | <u>\$ 1.73</u> | <u>\$ 1.06</u> |
| Diluted earnings per common share | <u>\$ 1.28</u> | <u>\$ 0.53</u> | <u>\$ 1.70</u> | <u>\$ 1.03</u> |

See accompanying notes to condensed consolidated financial statements.

Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| | For the six months ended | |
|--|--------------------------|---------------------|
| | June 30, | |
| | 2007 | 2006 |
| | (in thousands) | |
| Cash flows from operating activities | | |
| Net income | \$ 288,087 | \$ 173,204 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 94,328 | 71,502 |
| Gain on sale of investment securities, net | (85) | (58,064) |
| Stock-based compensation | 20,264 | 15,051 |
| Benefit for deferred income taxes | (24,011) | (1,226) |
| Changes in operating assets and liabilities, net of effect of businesses acquired: | | |
| Receivables | (16,612) | (42,957) |
| Other assets | (126,467) | (359,300) |
| Medical and other expenses payable | 465,885 | 526,763 |
| Other liabilities | 134,423 | 172,719 |
| Unearned revenues | 1,199,719 | 1,044,850 |
| Other, net | 16,216 | 286 |
| Net cash provided by operating activities | <u>2,051,747</u> | <u>1,542,828</u> |
| Cash flows from investing activities | | |
| Acquisitions, net of cash acquired | (27,005) | (25,931) |
| Purchases of property and equipment | (114,717) | (81,973) |
| Proceeds from sales of property and equipment | 4,072 | 2,156 |
| Purchases of investment securities | (1,873,295) | (2,258,548) |
| Maturities of investment securities | 769,956 | 1,010,397 |
| Proceeds from sales of investment securities | 926,603 | 712,685 |
| Change in securities lending collateral | (718,075) | (193,239) |
| Net cash used in investing activities | <u>(1,032,461)</u> | <u>(834,453)</u> |
| Cash flows from financing activities | | |
| Receipts from CMS contract deposits | 1,483,359 | 1,045,062 |
| Withdrawals from CMS contract deposits | (1,223,982) | (736,425) |
| Borrowings under credit agreement | 710,000 | 100,000 |
| Repayments under credit agreement | (760,000) | (300,000) |
| Proceeds from issuance of senior notes | — | 498,545 |
| Debt issue costs | — | (3,825) |
| Change in securities lending payable | 718,075 | 193,239 |
| Common stock repurchases | (7,203) | (4,937) |
| Change in book overdraft | (3,959) | (8,181) |
| Tax benefit from stock-based compensation | 14,554 | 13,656 |
| Proceeds from stock option exercises and other | 30,335 | 20,939 |
| Net cash provided by financing activities | <u>961,179</u> | <u>818,073</u> |
| Increase in cash and cash equivalents | 1,980,465 | 1,526,448 |
| Cash and cash equivalents at beginning of period | 1,740,304 | 732,016 |
| Cash and cash equivalents at end of period | <u>\$ 3,720,769</u> | <u>\$ 2,258,464</u> |
| Supplemental cash flow disclosures: | | |
| Interest payments | \$ 34,016 | \$ 29,821 |
| Income tax payments, net | \$ 124,933 | \$ 93,175 |

See accompanying notes to condensed consolidated financial statements.

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited

(1) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or those normally made in an Annual Report on Form 10-K. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2006, that was filed with the Securities and Exchange Commission, or the SEC, on February 23, 2007. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana,” mean Humana Inc. and its subsidiaries.

The preparation of our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of medical expenses payable, the impact of risk sharing provisions related to our Medicare and TRICARE contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. Refer to “Significant Accounting Policies” in Humana’s 2006 Annual Report on Form 10-K for information on accounting policies that the Company considers in preparing its consolidated financial statements.

The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.

(2) Recently Issued Accounting Pronouncements

In February 2007, the Financial Accounting Standards Board, or FASB, issued Statement of Financial Accounting Standards No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, or SFAS 159. SFAS 159 allows us an option to report selected financial assets and liabilities at fair value and establishes related presentation and disclosure requirements. We are required to adopt SFAS 159 in the first quarter of 2008. We currently are evaluating the provisions of SFAS 159. We do not expect the adoption of SFAS 159 to have a material impact on our financial position or results of operations.

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, *Fair Value Measurements*, or SFAS 157. SFAS 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 does not require new fair value measurements. We are required to adopt SFAS 157 in the first quarter of 2008. We currently are evaluating the provisions of SFAS 157. We do not expect the adoption of SFAS 157 to have a material impact on our financial position or results of operations.

(3) Acquisitions

In June 2007, our Commercial segment reached an agreement to acquire CompBenefits Corporation, an Atlanta-based provider of dental and vision benefit plans, for cash consideration of approximately \$360 million. The acquisition will be financed through a combination of cash and debt. This transaction, which is subject to regulatory approval, is expected to be completed later this year.

On March 1, 2007, our Government segment acquired DefenseWeb Technologies, Inc., or DefenseWeb, a company responsible for delivering customized software solutions for the Department of Defense, for cash consideration of approximately \$26.9 million.

On May 1, 2006 our Commercial segment acquired CHA Service Company, or CHA Health, a health plan serving employer groups in Kentucky, for cash consideration of approximately \$67.5 million.

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

(4) Medicare Part D

The condensed consolidated balance sheets include the following amounts associated with Medicare Part D as of June 30, 2007 and December 31, 2006. The risk corridor settlement includes amounts classified as long-term because settlement of balances associated with the 2007 contract year will exceed 12 months.

| | June 30, 2007 | | December 31, 2006 | |
|---|--------------------------------|--------------------|--------------------------------|-------------------|
| | Risk Corridor Settlement | CMS Subsidies | Risk Corridor Settlement | CMS Subsidies |
| | (in thousands) | | | |
| Other current assets | \$ 16,450 | \$ 643,688 | \$ 18,365 | \$ 449,984 |
| Trade accounts payable and accrued expenses | (744,591) | (780,799) | (757,084) | (327,718) |
| Net current (liability) asset | (728,141) | (137,111) | (738,719) | 122,266 |
| Other long-term assets | 107,212 | — | — | — |
| Other long-term liabilities | (69,310) | — | — | — |
| Net long-term asset | 37,902 | — | — | — |
| Total net (liability) asset | <u>\$(690,239)</u> | <u>\$(137,111)</u> | <u>\$(738,719)</u> | <u>\$ 122,266</u> |

(5) Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill, by operating segment, for the six months ended June 30, 2007 were as follows:

| | Commercial | Government (in thousands) | Total |
|------------------------------|------------------|------------------------------|--------------------|
| Balance at December 31, 2006 | \$782,501 | \$ 528,130 | \$1,310,631 |
| DefenseWeb acquisition | — | 19,954 | 19,954 |
| Balance at June 30, 2007 | <u>\$782,501</u> | <u>\$ 548,084</u> | <u>\$1,330,585</u> |

The following table presents details of our other intangible assets included in other long-term assets in the accompanying condensed consolidated balance sheets at June 30, 2007 and December 31, 2006:

| | Weighted Average Life at 6/30/07 | June 30, 2007 | | | December 31, 2006 | | |
|-------------------------------|--|------------------|-----------------------------|-----------------|-------------------|-----------------------------|-----------------|
| | | Cost | Accumulated Amortization | Net | Cost | Accumulated Amortization | Net |
| (in thousands) | | | | | | | |
| Other intangible assets: | | | | | | | |
| Subscriber contracts | 10.0 yrs | \$119,144 | \$ 44,596 | \$74,548 | \$114,944 | \$ 36,449 | \$78,495 |
| Provider contracts | 14.5 yrs | 11,500 | 2,415 | 9,085 | 11,500 | 2,012 | 9,488 |
| Licenses and other | 10.5 yrs | 11,881 | 3,107 | 8,774 | 11,602 | 3,929 | 7,673 |
| Total other intangible assets | 10.4 yrs | <u>\$142,525</u> | <u>\$ 50,118</u> | <u>\$92,407</u> | <u>\$138,046</u> | <u>\$ 42,390</u> | <u>\$95,656</u> |

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

Amortization expense for other intangible assets was approximately \$10.0 million for the six months ended June 30, 2007 and 2006. The following table presents our estimate of amortization expense for the remaining six months of 2007 and for each of the five next succeeding fiscal years:

| | (in thousands) |
|---|----------------|
| For the six month period ending December 31, 2007 | \$ 8,794 |
| For the years ending December 31, | |
| 2008 | \$ 15,455 |
| 2009 | \$ 11,475 |
| 2010 | \$ 10,459 |
| 2011 | \$ 9,871 |
| 2012 | \$ 9,102 |

(6) Comprehensive Income

The following table presents details supporting the computation of comprehensive income for the three and six months ended June 30, 2007 and 2006:

| | Three months ended June 30, | | Six months ended June 30, | |
|--|--------------------------------|------------------|------------------------------|------------------|
| | 2007 | 2006 | 2007 | 2006 |
| | (in thousands) | | | |
| Net income | \$216,846 | \$ 89,489 | \$288,087 | \$173,204 |
| Net unrealized investment losses, net of tax | (29,734) | (14,944) | (24,907) | (68,184) |
| Comprehensive income, net of tax | <u>\$187,112</u> | <u>\$ 74,545</u> | <u>\$263,180</u> | <u>\$105,020</u> |

(7) Earnings Per Common Share

The following table provides details supporting the computation of basic and diluted earnings per common share for the three and six months ended June 30, 2007 and 2006:

| | Three months ended June 30, | | Six months ended June 30, | |
|---|--|----------------|------------------------------|----------------|
| | 2007 | 2006 | 2007 | 2006 |
| | (in thousands, except per share results) | | | |
| Net income available for common stockholders | \$216,846 | \$ 89,489 | \$288,087 | \$173,204 |
| Weighted average outstanding shares of common stock used to compute basic earnings per common share | 166,614 | 163,706 | 166,213 | 163,411 |
| Dilutive effect of: | | | | |
| Employee stock options | 2,349 | 3,594 | 2,492 | 3,795 |
| Restricted stock | 633 | 236 | 571 | 224 |
| Shares used to compute diluted earnings per common share | <u>169,596</u> | <u>167,536</u> | <u>169,276</u> | <u>167,430</u> |
| Basic earnings per common share | <u>\$ 1.30</u> | <u>\$ 0.55</u> | <u>\$ 1.73</u> | <u>\$ 1.06</u> |
| Diluted earnings per common share | <u>\$ 1.28</u> | <u>\$ 0.53</u> | <u>\$ 1.70</u> | <u>\$ 1.03</u> |
| Number of antidilutive stock options and restricted stock excluded from computation | 932 | 1,044 | 1,260 | 770 |

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

(8) Income Taxes

The effective income tax rate was 36.1% for the three months ended June 30, 2007 and 36.2% for the six months ended June 30, 2007 compared to 36.2% for the three and six months ended June 30, 2006.

The Company and certain subsidiaries file income tax returns in the United States and certain foreign jurisdictions. During the first quarter of 2007, the Internal Revenue Service (IRS) completed its examination of our U.S. income tax returns for 2003 and 2004 resulting in immaterial adjustments. With few exceptions, which are immaterial in the aggregate, the Company is no longer subject to state, local and foreign tax examinations by tax authorities for years before 2003.

We adopted the provisions of FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes*, or FIN 48, on January 1, 2007. The liability for unrecognized tax benefits, including interest and penalties, at December 31, 2006 was \$15.6 million, all of which would affect the effective tax rate if recognized. There were no changes in the liability for unrecognized tax benefits as a result of the implementation of FIN 48. There are no positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next twelve months. We recognize penalties and interest accrued related to unrecognized tax benefits in tax expense. There were no material changes to the liability for unrecognized tax benefits or penalties and interest during the six months ended June 30, 2007.

(9) Guarantees and Contingencies

Government Contracts

Our Medicare business, which accounted for approximately 60% of our total premiums and ASO fees for the six months ended June 30, 2007, primarily consisted of products covered under the Medicare Advantage and stand-alone PDP contracts with the federal government. These contracts are renewed generally for a one-year term each December 31 unless CMS notifies Humana of its decision not to renew by May 1 of the preceding contract year, or Humana notifies CMS of its decision not to renew by the first Monday in June of the preceding contract year.

Our TRICARE business, which accounted for approximately 12% of our total premiums and ASO fees for the six months ended June 30, 2007, primarily consisted of the South Region contract. The 5-year South Region contract, which expires March 31, 2009, is subject to annual renewals on April 1 of each year at the government's option. Effective April 1, 2007, the South Region contract was extended into the fourth option period, which runs from April 1, 2007 to March 31, 2008. As required under the contract, the target underwritten health care cost and underwriting fee amounts for the fourth option period were negotiated. Any variance from the target health care cost is shared with the federal government. Accordingly, events and circumstances not contemplated in the negotiated target health care cost amount could have a material adverse effect on our business. These changes may include, for example, an increase or reduction in the number of persons enrolled or eligible to enroll due to the federal government's decision to increase or decrease U.S. military deployments. In the event government reimbursements were to decline from projected amounts, our failure to reduce the health care costs associated with these programs could have a material adverse effect on our business. A draft solicitation related to the new TRICARE contracts currently scheduled to begin April 1, 2009 was issued for industry comments. A final request for proposal is expected in late summer 2007. We expect to participate in the bid for these new contracts.

Our Medicaid business, which accounted for approximately 2% of our total premiums and ASO fees for the six months ended June 30, 2007, consisted of contracts in Puerto Rico and Florida, with a vast majority in Puerto Rico. Our Puerto Rico contracts expire September 30, 2007. The government of Puerto Rico has decided to delay the bid process for new contracts until as late as 2009. We currently are working with the Puerto Rico Health Insurance Administration and expect these efforts to result in a satisfactory relationship going forward. We are unable to predict the ultimate impact that any government policy or fiscal decisions might have on the continuation of our Medicaid contracts in Puerto Rico.

The loss of any of the contracts above or significant changes in these programs as a result of legislative action, including reductions in premium payments to us, or increases in member benefits without corresponding increases in premium payments to us, may have a material adverse effect on our financial position, results of operations, and cash flows.

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

Legal Proceedings

Our current and past business practices are subject to review by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, competitive practices, commission payments, privacy issues, utilization management practices, and sales practices. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.

We also are involved in various lawsuits that arise, for the most part, in the ordinary course of our business operations, including employment litigation, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, failure to disclose network discounts and various other provider arrangements, intellectual property matters, and challenges to subrogation practices. We also are subject to claims relating to performance of contractual obligations to providers, members, and others, including failure to properly pay claims, challenges to our implementation of the new Medicare prescription drug program and other litigation.

Personal injury claims and claims for extracontractual damages arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.

The outcome of current suits or likelihood or outcome of future suits or governmental investigations cannot be accurately predicted with certainty, and therefore, such legal actions and government audits and investigations could have a material adverse effect on our financial position, results of operations, and cash flows.

(10) Segment Information

We manage our business with two segments: Government and Commercial. The Government segment consists of members enrolled in government-sponsored programs, and includes three lines of business: Medicare, TRICARE, and Medicaid. The Commercial segment consists of members enrolled in products marketed to employer groups and individuals, and includes two lines of business: medical (fully and self insured) and specialty. We identified our segments in accordance with the aggregation provisions of SFAS No. 131, *Disclosures About Segments of an Enterprise and Related Information*, or SFAS 131, which is consistent with information used by our Chief Executive Officer in managing our business. The segment information aggregates products with similar economic characteristics. These characteristics include the nature of customer groups and pricing, benefits and underwriting requirements.

The accounting policies of each segment are the same and are described in Note 2 to the consolidated financial statements included in our Form 10-K for the year ended December 31, 2006. The results of each segment are measured by income before income taxes. We allocate all selling, general and administrative expenses, investment and other revenue, interest expense, and goodwill, but no other assets or liabilities, to our segments. Members served by our two segments often utilize the same medical provider networks, enabling us to obtain more favorable contract terms with providers. Our segments also share indirect overhead costs and assets. As a result, the profitability of each segment is interdependent.

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

Our segment results were as follows for the three and six months ended June 30, 2007 and 2006:

| | Government Segment | | | |
|-------------------------------------|-----------------------------|-------------|---------------------------|-------------|
| | Three months ended June 30, | | Six months ended June 30, | |
| | 2007 | 2006 | 2007 | 2006 |
| | (in thousands) | | | |
| Revenues: | | | | |
| Premiums: | | | | |
| Medicare Advantage | \$2,804,438 | \$2,109,406 | \$5,547,149 | \$3,830,249 |
| Medicare stand-alone PDP | 1,051,259 | 801,755 | 1,957,685 | 1,316,912 |
| Total Medicare | 3,855,697 | 2,911,161 | 7,504,834 | 5,147,161 |
| TRICARE | 725,040 | 657,627 | 1,452,255 | 1,258,381 |
| Medicaid | 132,486 | 129,158 | 261,811 | 258,625 |
| Total premiums | 4,713,223 | 3,697,946 | 9,218,900 | 6,664,167 |
| Administrative services fees | 17,671 | 11,144 | 34,061 | 22,335 |
| Investment income | 42,354 | 23,467 | 85,592 | 35,738 |
| Other revenue | 383 | 457 | 767 | 984 |
| Total revenues | 4,773,631 | 3,733,014 | 9,339,320 | 6,723,224 |
| Operating expenses: | | | | |
| Medical | 3,972,110 | 3,180,569 | 7,995,518 | 5,718,443 |
| Selling, general and administrative | 472,282 | 425,350 | 962,244 | 835,134 |
| Depreciation and amortization | 31,009 | 21,211 | 54,930 | 40,517 |
| Total operating expenses | 4,475,401 | 3,627,130 | 9,012,692 | 6,594,094 |
| Income from operations | 298,230 | 105,884 | 326,628 | 129,130 |
| Interest expense | 9,440 | 7,903 | 19,973 | 9,577 |
| Income before income taxes | \$ 288,790 | \$ 97,981 | \$ 306,655 | \$ 119,553 |

Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Unaudited

| | Commercial Segment | | | |
|-------------------------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|
| | Three months ended June 30, | Three months ended June 30, | Six months ended June 30, | Six months ended June 30, |
| | 2007 | 2006 | 2007 | 2006 |
| | (in thousands) | | | |
| Revenues: | | | | |
| Premiums: | | | | |
| Fully-insured | | | | |
| PPO | \$ 918,223 | \$ 919,238 | \$1,845,729 | \$1,825,119 |
| HMO | 483,859 | 545,408 | 947,158 | 1,093,459 |
| Total fully-insured | 1,402,082 | 1,464,646 | 2,792,887 | 2,918,578 |
| Specialty | 107,945 | 101,883 | 216,026 | 203,216 |
| Total premiums | 1,510,027 | 1,566,529 | 3,008,913 | 3,121,794 |
| Administrative services fees | 79,422 | 72,567 | 158,896 | 140,054 |
| Investment income | 29,698 | 27,100 | 59,987 | 113,731 |
| Other revenue | 34,019 | 7,959 | 64,494 | 12,731 |
| Total revenues | 1,653,166 | 1,674,155 | 3,292,290 | 3,388,310 |
| Operating expenses: | | | | |
| Medical | 1,218,308 | 1,298,932 | 2,408,900 | 2,544,984 |
| Selling, general and administrative | 354,177 | 308,513 | 684,825 | 639,615 |
| Depreciation and amortization | 23,255 | 15,385 | 39,398 | 30,985 |
| Total operating expenses | 1,595,740 | 1,622,830 | 3,133,123 | 3,215,584 |
| Income from operations | 57,426 | 51,325 | 159,167 | 172,726 |
| Interest expense | 6,626 | 8,984 | 14,011 | 20,749 |
| Income before income taxes | \$ 50,800 | \$ 42,341 | \$ 145,156 | \$ 151,977 |

Humana Inc.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company's financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to "we," "us," "our," "Company," and "Humana" mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like "expects," "anticipates," "intends," "likely will result," "estimates," "projects" or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our Form 10-K for the year ended December 31, 2006 that was filed with the SEC on February 23, 2007. In making these statements, we are not undertaking to address or update these factors in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Overview

Headquartered in Louisville, Kentucky, Humana Inc. is one of the nation's largest publicly traded health benefits companies, based on our 2006 revenues of \$21.4 billion. We offer a diversified portfolio of health insurance products and related services through traditional and consumer-choice plans for government-sponsored programs, employer groups, and individuals. As of June 30, 2007, we had approximately 11.3 million members in our medical benefit programs, as well as approximately 1.9 million members in our specialty products programs.

We manage our business with two segments: Government and Commercial. The Government segment consists of members enrolled in government-sponsored programs, and includes three lines of business: Medicare, TRICARE, and Medicaid. The Commercial segment consists of members enrolled in products marketed to employer groups and individuals, and includes two lines of business: medical (fully and self insured) and specialty. We identified our segments in accordance with the aggregation provisions of SFAS 131, which is consistent with information used by our Chief Executive Officer in managing our business. The segment information aggregates products with similar economic characteristics. These characteristics include the nature of customer groups and pricing, benefits and underwriting requirements.

The results of each segment are measured by income before income taxes. We allocate all selling, general and administrative expenses, investment and other revenue, interest expense, and goodwill, but no other assets or liabilities, to our segments. Members served by our two segments often utilize the same medical provider networks, enabling us to obtain more favorable contract terms with providers. Our segments also share overhead costs and assets. As a result, the profitability of each segment is interdependent.

Our results are impacted by many factors, but most notably are influenced by our ability to establish and maintain a competitive and efficient cost structure and to accurately and consistently establish competitive premium, ASO fee, and plan benefit levels that are commensurate with our medical and administrative costs. Medical costs are subject to a high rate of inflation due to many forces, including new higher priced technologies and medical procedures, increasing capacity and supply of medical services, new prescription drugs and therapies, an aging population, lifestyle challenges including obesity and smoking, the tort liability system, and government regulation.

Our industry relies on two key statistics to measure performance. The medical expense ratio, or MER, which is computed by taking total medical expenses as a percentage of premium revenues, represents a statistic used to measure underwriting profitability. The selling, general, and administrative expense ratio, or SG&A expense ratio, which is computed by taking total selling, general and administrative expenses as a percentage of premium revenues, administrative services fees and other revenue, represents a statistic used to measure administrative spending efficiency.

Government Segment

Our strategy and commitment to the expanded Medicare programs, including new product choices and pharmacy benefits for seniors, has led to significant growth. Medicare Advantage membership increased to 1,133,700 members at June 30, 2007, up 18.1% from 959,800 at June 30, 2006, primarily due to sales of Private

[Table of Contents](#)

Fee-For-Service, or PFFS, products. Average Medicare Advantage membership was 27.5% higher in the second quarter of 2007 compared to the second quarter of 2006, and average stand-alone PDP membership was 20.7% higher. Likewise, Medicare premium revenues have increased 32.4% to \$3.9 billion for the second quarter of 2007 from \$2.9 billion in the second quarter of 2006.

Our quarterly Government segment earnings are particularly impacted by seasonality associated with the Medicare Part D benefit structure. The Medicare Part D benefit design results in coverage that varies as a member's cumulative out-of-pocket costs pass through successive stages of a member's plan period which begins January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total pharmacy costs in the early stages and less in the latter stages. As a result, we expect a lower medical expense ratio from our Government segment during the second half of 2007.

Commercial Segment

We continue to increase the diversification of our Commercial segment membership base and continue to exercise pricing discipline relative to our fully-insured accounts. Commercial segment medical membership decreased by 35,200 members from June 30, 2006 to 3,278,700 at June 30, 2007 as a result of a decline in the fully-insured group product membership partially offset by enrollment gains in the individual, consumer-choice, and ASO products. MER declined to 80.7% during the second quarter of 2007 compared to 82.9% in the second quarter of 2006. ASO membership at June 30, 2007 was up 7.9% from June 30, 2006. Individual membership increased 20.6% and fully-insured consumer-choice membership increased 31.0% since June 30, 2006. These three areas, together with our small group business, now represent more than 80% of our Commercial medical membership.

Other Highlights

- Year over year comparisons were impacted by a gain in the prior year first quarter of \$51.7 million pretax, or \$0.19 per diluted common share, from the sale of a venture capital investment.
- Cash flows from operations increased \$508.9 million to \$2,051.7 million in the first half of 2007 compared to \$1,542.8 million in the first half of 2006. Operating cash flows included the receipt in late June of Medicare premiums for July of \$1,175.3 million and \$1,031.7 million in the first half of 2007 and 2006, respectively.
- Debt-to-total capitalization decreased 350 basis points to 26.1% at June 30, 2007 compared to 29.6% at March 31, 2007 primarily due to the repayment of first quarter 2007 borrowings against the company's credit facility.
- On June 15, 2007 we announced a voluntary, temporary suspension of individual Medicare PFFS marketing in conjunction with other industry participants. CMS has indicated that they are prepared to review and approve our compliance with regulatory requirements prior to the 2008 open enrollment season which begins October 1.

We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain critical accounting principles and estimates impact our financial statements.

Recent Acquisitions

In June 2007, our Commercial segment reached an agreement to acquire CompBenefits Corporation, an Atlanta-based provider of dental and vision benefit plans, for cash consideration of approximately \$360 million. The acquisition will be financed through a combination of cash and debt. This transaction, which is subject to regulatory approval, is expected to be completed later this year.

On March 1, 2007, our Government segment acquired DefenseWeb Technologies, Inc., a company responsible for delivering customized software solutions for the Department of Defense, for cash consideration of approximately \$26.9 million. We expect this transaction will not have a material impact on our results of operations or cash flows from operations for 2007.

On May 1, 2006 our Commercial segment acquired CHA Service Company, or CHA Health, a health plan serving employer groups in Kentucky, for cash consideration of approximately \$67.5 million.

Table of Contents

Recently Issued Accounting Pronouncements

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, or SFAS 159. SFAS 159 allows us an option to report selected financial assets and liabilities at fair value and establishes related presentation and disclosure requirements. We are required to adopt SFAS 159 in the first quarter of 2008. We currently are evaluating the provisions of SFAS 159. We do not expect the adoption of SFAS 159 to have a material impact on our financial position or results of operations.

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, *Fair Value Measurements*, or SFAS 157. SFAS 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 does not require new fair value measurements. We are required to adopt SFAS 157 in the first quarter of 2008. We currently are evaluating the provisions of SFAS 157. We do not expect the adoption of SFAS 157 to have a material impact on our financial position or results of operations.

Comparison of Results of Operations for 2007 and 2006

The following discussion primarily deals with our results of operations for the three months ended June 30, 2007, or the 2007 quarter, the three months ended June 30, 2006, or the 2006 quarter, the six months ended June 30, 2007, or the 2007 period, and the six months ended June 30, 2006, or the 2006 period.

The following table presents certain financial data for our two segments:

| | For the three months ended June 30, | | Change | |
|---|--|-------------|------------|------------|
| | 2007 | 2006 | Dollars | Percentage |
| | (in thousands, except ratios) | | | |
| Premium revenues: | | | | |
| Medicare Advantage | \$2,804,438 | \$2,109,406 | \$ 695,032 | 32.9% |
| Medicare stand-alone PDP | 1,051,259 | 801,755 | 249,504 | 31.1% |
| Total Medicare | 3,855,697 | 2,911,161 | 944,536 | 32.4% |
| TRICARE | 725,040 | 657,627 | 67,413 | 10.3% |
| Medicaid | 132,486 | 129,158 | 3,328 | 2.6% |
| Total Government | 4,713,223 | 3,697,946 | 1,015,277 | 27.5% |
| Fully-insured | 1,402,082 | 1,464,646 | (62,564) | (4.3)% |
| Specialty | 107,945 | 101,883 | 6,062 | 5.9% |
| Total Commercial | 1,510,027 | 1,566,529 | (56,502) | (3.6)% |
| Total | \$6,223,250 | \$5,264,475 | \$ 958,775 | 18.2% |
| Administrative services fees: | | | | |
| Government | \$ 17,671 | \$ 11,144 | \$ 6,527 | 58.6% |
| Commercial | 79,422 | 72,567 | 6,855 | 9.4% |
| Total | \$ 97,093 | \$ 83,711 | \$ 13,382 | 16.0% |
| Income before income taxes: | | | | |
| Government | \$ 288,790 | \$ 97,981 | \$ 190,809 | 194.7% |
| Commercial | 50,800 | 42,341 | 8,459 | 20.0% |
| Total | \$ 339,590 | \$ 140,322 | \$ 199,268 | 142.0% |
| Medical expense ratios ^(a) : | | | | |
| Government | 84.3% | 86.0% | | (1.7)% |
| Commercial | 80.7% | 82.9% | | (2.2)% |
| Total | 83.4% | 85.1% | | (1.7)% |
| SG&A expense ratios ^(b) : | | | | |
| Government | 10.0% | 11.5% | | (1.5)% |
| Commercial | 21.8% | 18.7% | | 3.1% |
| Total | 13.0% | 13.7% | | (0.7)% |

[Table of Contents](#)

| | For the six months ended June 30, | | Change | |
|---|--------------------------------------|-------------|-------------|------------|
| | 2007 | 2006 | Dollars | Percentage |
| | (in thousands, except ratios) | | | |
| Premium revenues: | | | | |
| Medicare Advantage | \$ 5,547,149 | \$3,830,249 | \$1,716,900 | 44.8% |
| Medicare PDP | 1,957,685 | 1,316,912 | 640,773 | 48.7% |
| Total Medicare | 7,504,834 | 5,147,161 | 2,357,673 | 45.8% |
| TRICARE | 1,452,255 | 1,258,381 | 193,874 | 15.4% |
| Medicaid | 261,811 | 258,625 | 3,186 | 1.2% |
| Total Government | 9,218,900 | 6,664,167 | 2,554,733 | 38.3% |
| Fully-insured | 2,792,887 | 2,918,578 | (125,691) | (4.3)% |
| Specialty | 216,026 | 203,216 | 12,810 | 6.3% |
| Total Commercial | 3,008,913 | 3,121,794 | (112,881) | (3.6)% |
| Total | \$12,227,813 | \$9,785,961 | \$2,441,852 | 25.0% |
| Administrative services fees: | | | | |
| Government | \$ 34,061 | \$ 22,335 | \$ 11,726 | 52.5% |
| Commercial | 158,896 | 140,054 | 18,842 | 13.5% |
| Total | \$ 192,957 | \$ 162,389 | \$ 30,568 | 18.8% |
| Income before income taxes: | | | | |
| Government | \$ 306,655 | \$ 119,553 | \$ 187,102 | 156.5% |
| Commercial | 145,156 | 151,977 | (6,821) | (4.5)% |
| Total | \$ 451,811 | \$ 271,530 | \$ 180,281 | 66.4% |
| Medical expense ratios ^(a) : | | | | |
| Government | 86.7% | 85.8% | | 0.9% |
| Commercial | 80.1% | 81.5% | | (1.4)% |
| Total | 85.1% | 84.4% | | 0.7% |
| SG&A expense ratios ^(b) : | | | | |
| Government | 10.4% | 12.5% | | (2.1)% |
| Commercial | 21.2% | 19.5% | | 1.7% |
| Total | 13.2% | 14.8% | | (1.6)% |

(a) Represents total medical expenses as a percentage of premium revenue. Also known as the MER.

(b) Represents total selling, general, and administrative expenses as a percentage of premium revenues, administrative services fees, and other revenue. Also known as the SG&A expense ratio.

Table of Contents

Ending medical membership was as follows at June 30, 2007 and 2006:

| | June 30, | | Change | |
|-------------------------------------|------------|------------|-----------|------------|
| | 2007 | 2006 | Members | Percentage |
| Government segment medical members: | | | | |
| Medicare Advantage | 1,133,700 | 959,800 | 173,900 | 18.1% |
| Medicare stand-alone PDP | 3,440,100 | 3,458,800 | (18,700) | (0.5)% |
| Total Medicare | 4,573,800 | 4,418,600 | 155,200 | 3.5% |
| TRICARE | 1,717,600 | 1,732,600 | (15,000) | (0.9)% |
| TRICARE ASO | 1,150,600 | 1,141,900 | 8,700 | 0.8% |
| Total TRICARE | 2,868,200 | 2,874,500 | (6,300) | (0.2)% |
| Medicaid | 384,900 | 418,500 | (33,600) | (8.0)% |
| Medicaid ASO | 182,700 | — | 182,700 | 100.0% |
| Total Medicaid | 567,600 | 418,500 | 149,100 | 35.6% |
| Total Government | 8,009,600 | 7,711,600 | 298,000 | 3.9% |
| Commercial segment medical members: | | | | |
| Fully-insured | 1,746,300 | 1,893,100 | (146,800) | (7.8)% |
| ASO | 1,532,400 | 1,420,800 | 111,600 | 7.9% |
| Total Commercial | 3,278,700 | 3,313,900 | (35,200) | (1.1)% |
| Total medical membership | 11,288,300 | 11,025,500 | 262,800 | 2.4% |

These tables of financial data should be reviewed in connection with the discussion that follows.

Summary

Net income was \$216.8 million, or \$1.28 per diluted common share, in the 2007 quarter compared to \$89.5 million, or \$0.53 per diluted common share, in the 2006 quarter. Net income was \$288.1 million, or \$1.70 per diluted common share, in the 2007 period compared to \$173.2 million, or \$1.03 per diluted common share, in the 2006 period. The 2006 period's net income included \$32.2 million, or \$0.19 per diluted common share, from the sale of a venture capital investment in the first quarter. Excluding the venture capital gain, the year-over-year increase in earnings resulted from higher operating earnings in both our Government and Commercial segments, primarily driven by efficiency gains in our consolidated administrative costs as well as improvement in our medical expense ratio in each segment.

Premium Revenues and Medical Membership

Premium revenues increased \$0.9 billion, or 18.2%, to \$6.2 billion for the 2007 quarter, compared to \$5.3 billion for the 2006 quarter. For the 2007 period, premium revenues were \$12.2 billion, an increase of \$2.4 billion, or 25.0%, compared to \$9.8 billion for the 2006 period. Higher Government segment premium revenues were partially offset by a decrease in Commercial segment premium revenues. Premium revenues reflect changes in membership and increases in average per member premiums. Items impacting average per member premiums include changes in premium rates as well as changes in the geographic mix of membership, the mix of product offerings, and the mix of benefit plans selected by our membership.

Government segment premium revenues increased \$1.0 billion, or 27.5%, to \$4.7 billion for the 2007 quarter, compared to \$3.7 billion for the 2006 quarter. For the 2007 period, Government segment premium revenues were \$9.2 billion, an increase of \$2.5 billion, or 38.3%, compared to \$6.7 billion for the 2006 period. This increase primarily was attributable to higher average Medicare membership from the expanded participation in various Medicare products. Average membership is calculated by summing the ending membership for each month in a period and dividing the result by the number of months in a period. Average Medicare Advantage membership increased 27.5% for the 2007 quarter and 41.4% for the 2007 period. Sales of our PFFS products drove the majority of the 173,900 increase in Medicare Advantage members since June 30, 2006. Average Medicare stand-alone PDP membership increased 20.7% for the 2007 quarter, and 51.4% for the 2007 period. Medicaid membership increased by 149,100 members from June 30, 2006 to June 30, 2007 primarily due to the award of a new Puerto Rico ASO contract during the fourth quarter of 2006. The increase has been partially offset by eligible Puerto Rico Medicaid members choosing to move into the Medicare Advantage program.

[Table of Contents](#)

Commercial segment premium revenues decreased \$56.5 million, or 3.6%, to \$1.5 billion for the 2007 quarter. For the 2007 period, Commercial segment premium revenues decreased \$112.9 million, or 3.6%, to \$3.0 billion compared to \$3.1 billion for the 2006 period. Lower premium revenues primarily resulted from a reduction of fully-insured membership partially offset by increases in average per member premiums. Our fully-insured membership decreased 7.8%, or 146,800 members, to 1,746,300 at June 30, 2007 compared to 1,893,100 at June 30, 2006 primarily as a result of a large group account moving from fully-insured to ASO on July 1, 2006, partially offset by membership gains in the small group, individual, and consumer-choice product lines. Average per member premiums for our fully-insured group medical members increased approximately 5% for the 2007 quarter and 2007 period. In addition, the 2007 period was impacted by the CHA Health acquisition which added \$30.9 million in premium revenues.

Administrative Services Fees

Our administrative services fees for the 2007 quarter were \$97.1 million, an increase of \$13.4 million, or 16.0%, from \$83.7 million for the 2006 quarter. For the 2007 period, administrative services fees were \$193.0 million, an increase of \$30.6 million, or 18.8%, from \$162.4 million for the 2006 period. The increase was due to increases in both our Commercial and Government segments.

For the Commercial segment, administrative services fees increased \$6.8 million, or 9.4%, from \$72.6 million for the 2006 quarter to \$79.4 million for the 2007 quarter. For the 2007 period, Commercial segment administrative services fees increased \$18.8 million, or 13.5%, from \$140.1 million for the 2006 period to \$158.9 million for the 2007 period. This increase resulted from increased ASO membership and higher average per member fees. ASO membership of 1,420,800 members at June 30, 2006 increased 7.9% to 1,532,400 at June 30, 2007. Average per member fees increased approximately 3.2% in the 2007 quarter and approximately 6.3% in the 2007 period.

For the Government segment, administrative services fees increased \$6.5 million, or 58.6%, to \$17.7 million for the 2007 quarter. For the 2007 period, Government segment administrative services fees increased \$11.8 million, or 52.5%, from \$22.3 million for the 2006 period to \$34.1 million for the 2007 period. This increase resulted from the DefenseWeb acquisition and the award of a new Puerto Rico ASO contract during the fourth quarter of 2006.

Investment Income

Investment income totaled \$72.1 million for the 2007 quarter, an increase of \$21.5 million from \$50.6 million for the 2006 quarter primarily due to higher average invested balances. Investment income totaled \$145.6 million for the 2007 period, a decrease of \$3.9 million from \$149.5 million for the 2006 period. The 2006 period included a \$51.7 million gain realized related to the sale of a venture capital investment in the first quarter. Excluding the venture capital gain, investment income increased primarily due to higher average invested balances.

Other Revenue

Other revenue totaled \$34.4 million for the 2007 quarter, an increase of \$26.0 million from \$8.4 million for the 2006 quarter. Other revenue totaled \$65.3 million for the 2007 period, an increase of \$51.6 million from \$13.7 million for the 2006 period. The increase primarily was attributable to increased revenue from growth related to *RightSource*SM, our mail order pharmacy.

Medical Expense

Consolidated medical expenses increased \$710.9 million, or 15.9%, during the 2007 quarter compared to the 2006 quarter. For the 2007 period, consolidated medical expense was \$10.4 billion, an increase of \$2.1 billion, or 25.9%, from the 2006 period. The increase primarily was driven by the increase in the number of Medicare members and an increase in average per member claims costs primarily from the effects of health care inflation.

The consolidated MER for the 2007 quarter was 83.4%, a 170 basis point decrease from 85.1% for the 2006 quarter due to improvements in MER for both the Commercial and Government segments. The consolidated MER for the 2007 period was 85.1%, an increase of 70 basis points from the 2006 period rate of 84.4%. An improvement in the Commercial segment MER was offset by a higher Government segment MER associated with the Medicare Part D business.

The Government segment's medical expenses increased \$791.5 million, or 24.9%, during the 2007 quarter compared to the 2006 quarter. For the 2007 period, the Government segment's medical expenses increased \$2.3 billion, or 39.8%, from the 2006 period. The increase primarily was due to an increase in the average number of Medicare members, including those enrolled in our PDPs, and to a lesser extent, an increase in average per member claims costs.

[Table of Contents](#)

The Government segment's MER for the 2007 quarter was 84.3%, a 170 basis point decrease from the 2006 quarter rate of 86.0%, reflecting a more normal MER pattern for the Part D benefit for 2007. For the 2007 period, the Government segment's MER was 86.7%, an increase of 90 basis points from the 2006 period rate of 85.8%. The MER for the 2007 period included the combined effect of a seasonal pattern of higher medical expenses during the first half of the year associated with Part D benefits together with an increase in average stand-alone PDP membership for the 2007 period versus the 2006 period. The Part D benefit designs result in us sharing a greater portion of the responsibility for total pharmacy costs in the early stages of a member's plan period and less in the later stages, resulting in a declining MER as the year progresses. The extended enrollment period in 2006, which ended June 30, 2006, skewed the standard pattern associated with the progression of members through the stages of Part D benefits. Following the reset of the benefit on January 1, 2007, we expect the total Medicare MER to decrease each sequential quarter of 2007.

The Commercial segment's medical expenses decreased \$80.6 million, or 6.2%, from the 2006 quarter to the 2007 quarter. For the 2007 period, the Commercial segment's medical expenses decreased \$136.1 million, or 5.3%, from the 2006 period. This decrease primarily results from the decrease in fully-insured group membership partially offset by the increase in average per member claims costs. The increase in average per member claims costs for fully-insured group members was consistent with the increase in average per member premiums for the 2007 quarter and 2007 period, and is expected to rise in the range of 4.5% to 5.0% for the full year 2007. In addition, the 2007 period was impacted by the CHA Health acquisition which added \$25.2 million in medical expenses.

The MER for the Commercial segment of 80.7% in the 2007 quarter decreased 220 basis points from the 2006 quarter MER of 82.9%. For the 2007 period, the Commercial segment's MER of 80.1% decreased 140 basis points from the 2006 period MER of 81.5%. The decrease in MER primarily reflects improving medical cost utilization trends and an increase in the percentage of individual and small group members comprising our total fully-insured block. Individual and smaller group accounts generally carry a lower MER than larger group accounts.

SG&A Expense

Consolidated SG&A expenses increased \$92.6 million, or 12.6%, during the 2007 quarter compared to the 2006 quarter. For the 2007 period, consolidated SG&A expenses increased \$172.3 million, or 11.7%, from the 2006 period. The increase primarily resulted from an increase in the number of employees and increased sales and marketing costs due to the Medicare expansion, as well as expenses associated with *RightSource*SM, our mail order pharmacy.

The consolidated SG&A expense ratio for the 2007 quarter was 13.0%, decreasing 70 basis points from 13.7% for the 2006 quarter. For the 2007 period, the consolidated SG&A expense ratio was 13.2%, decreasing 160 basis points from 14.8% for the 2006 period. The SG&A expense ratio decrease resulted from improving administrative cost efficiency and productivity gains associated with servicing our members. The consolidated SG&A expense ratio is expected to be in the range of 13% to 14% for the full year 2007.

Our Government and Commercial segments bear direct and indirect overhead SG&A expenses. We allocate indirect overhead expenses shared by the two segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.

SG&A expenses in the Government segment increased \$46.9 million, or 11.0%, during the 2007 quarter compared to the 2006 quarter. For the 2007 period, SG&A expenses of \$962.2 million increased \$127.1 million, or 15.2%, from the 2006 period. The Government segment SG&A expense ratio decreased 150 basis points from 11.5% for the 2006 quarter to 10.0% for the 2007 quarter. For the 2007 period, the Government segment SG&A expense ratio of 10.4% decreased 210 basis points from 12.5% for the 2006 period. These changes resulted from efficiency and productivity gains associated with servicing higher average Medicare membership.

The Commercial segment SG&A expenses increased \$45.7 million, or 14.8%, during the 2007 quarter compared to the 2006 quarter. The Commercial segment SG&A expenses increased \$45.2 million, or 7.1%, during the 2007 period compared to the 2006 period. The Commercial segment SG&A expense ratio increased 310 basis points from 18.7% for the 2006 quarter to 21.8% for the 2007 quarter. For the 2007 period, the Commercial segment SG&A expense ratio of 21.2% increased 170 basis points from 19.5% for the 2006 period. This increase primarily resulted from the continued shift in the mix of membership towards ASO, an increase in the percentage of individual and small group members comprising our fully-insured membership, and administrative costs associated with increased business for our mail order pharmacy. At June 30, 2007, 46.7% of our Commercial segment medical membership was related to ASO business compared to 42.9% at June 30, 2006. Likewise, 29.4% of our Commercial segment medical membership was related to individual and small group accounts compared to 27.8% at June 30, 2006. ASO business carries a significantly higher SG&A ratio than fully-insured business, and individual and small group accounts bear a higher SG&A ratio as compared to larger accounts.

[Table of Contents](#)

Depreciation and Amortization

Depreciation and amortization for the 2007 quarter totaled \$54.3 million compared to \$36.6 million for the 2006 quarter, an increase of \$17.7 million, or 48.4%. Depreciation and amortization for the 2007 period totaled \$94.3 million compared to \$71.5 million for the 2006 period, an increase of \$22.8 million, or 31.9%. The increase resulted primarily from shortening the useful life associated with abandoning equipment and software during the 2007 quarter, and from capital expenditures related to the Medicare expansion.

Interest Expense

Interest expense was \$16.1 million for the 2007 quarter, compared to \$16.9 million for the 2006 quarter, a decrease of \$0.8 million primarily due to lower interest rates. Interest expense was \$34.0 million for the 2007 period, compared to \$30.3 million for the 2006 period, an increase of \$3.7 million. This increase primarily resulted from higher average outstanding debt.

Income Taxes

Our effective tax rate during the 2007 period of 36.2% was comparable to the effective tax rate in the 2006 period.

Membership

The following table presents our medical and specialty membership at June 30, 2007, March 31, 2007, and at the end of each quarter in 2006:

| | 2007 | | 2006 | | | |
|------------------------------|------------|------------|------------|------------|------------|-----------|
| | June 30 | March 31 | Dec. 31 | Sept. 30 | June 30 | March 31 |
| Medical Membership: | | | | | | |
| Government segment: | | | | | | |
| Medicare Advantage | 1,133,700 | 1,113,400 | 1,002,600 | 993,000 | 959,800 | 741,200 |
| Medicare stand-alone PDP | 3,440,100 | 3,473,700 | 3,536,600 | 3,521,000 | 3,458,800 | 1,959,000 |
| Total Medicare | 4,573,800 | 4,587,100 | 4,539,200 | 4,514,000 | 4,418,600 | 2,700,200 |
| TRICARE | 1,717,600 | 1,712,900 | 1,716,400 | 1,721,300 | 1,732,600 | 1,724,700 |
| TRICARE ASO | 1,150,600 | 1,165,500 | 1,163,600 | 1,141,400 | 1,141,900 | 1,149,300 |
| Total TRICARE | 2,868,200 | 2,878,400 | 2,880,000 | 2,862,700 | 2,874,500 | 2,874,000 |
| Medicaid | 384,900 | 384,000 | 390,700 | 412,600 | 418,500 | 427,000 |
| Medicaid ASO | 182,700 | 175,400 | 178,400 | — | — | — |
| Total Medicaid | 567,600 | 559,400 | 569,100 | 412,600 | 418,500 | 427,000 |
| Total Government | 8,009,600 | 8,024,900 | 7,988,300 | 7,789,300 | 7,711,600 | 6,001,200 |
| Commercial segment: | | | | | | |
| Fully-insured | 1,746,300 | 1,728,100 | 1,754,200 | 1,779,900 | 1,893,100 | 1,864,200 |
| ASO | 1,532,400 | 1,529,400 | 1,529,600 | 1,512,000 | 1,420,800 | 1,395,200 |
| Total Commercial | 3,278,700 | 3,257,500 | 3,283,800 | 3,291,900 | 3,313,900 | 3,259,400 |
| Total medical members | 11,288,300 | 11,282,400 | 11,272,100 | 11,081,200 | 11,025,500 | 9,260,600 |
| Specialty Membership: | | | | | | |
| Commercial segment | 1,930,000 | 1,935,200 | 1,902,800 | 1,899,700 | 1,894,900 | 1,882,300 |

Liquidity

Our primary sources of cash include receipts of premiums, ASO fees, CMS settlements, investment income, as well as proceeds from the sale or maturity of our investment securities and from borrowings. Our primary uses of cash include disbursements for claims payments, SG&A expenses, CMS settlements, interest expense, taxes, purchases of investment securities, capital expenditures, acquisitions, and payments on borrowings. Because premiums generally are collected in advance of claim payments by a period of up to several months in many instances, our business should normally produce positive cash flows during a period of increasing enrollment. Conversely, cash flows would be negatively impacted during a period of shrinking enrollment. We have recently been experiencing improving operating cash flows associated with growth in Medicare enrollment. The use of operating cash flows may be limited by regulatory requirements which require, among other items, that our regulated subsidiaries maintain minimum levels of capital.

Table of Contents

Cash and cash equivalents increased to \$3,720.8 million at June 30, 2007 from \$1,740.3 million at December 31, 2006. The increase in cash and cash equivalents primarily was due to the early receipt of the July Medicare premium remittance and an increase in operating cash flows. The early receipt of the July Medicare premium remittance also resulted in an increase to unearned revenue in our condensed consolidated balance sheet at June 30, 2007. The change in cash and cash equivalents for the six months ended June 30, 2007 and 2006 is summarized as follows:

| | 2007 | 2006 |
|---|---------------------|--------------------|
| | (in thousands) | |
| Net cash provided by operating activities | \$ 2,051,747 | \$1,542,828 |
| Net cash used in investing activities | (1,032,461) | (834,453) |
| Net cash provided by financing activities | 961,179 | 818,073 |
| Increase in cash and cash equivalents | <u>\$ 1,980,465</u> | <u>\$1,526,448</u> |

Cash Flow from Operating Activities

Our operating cash flows for the 2007 and 2006 periods were significantly impacted by the timing of the Medicare premium remittance which is payable to us on the first day of each month. When the first day of a month falls on a weekend or holiday, generally with the exception of January 1 (New Year's Day), we receive this payment at the end of the previous month. As such, Medicare receipts for July 2007 of \$1,175.3 million and July 2006 of \$1,031.7 million were received in the second quarter of 2007 and 2006 (late June in each case) because July 1 fell on a weekend. This also resulted in an increase to unearned revenues in our condensed consolidated balance sheet at June 30, 2007.

In addition to the impact from the timing of the Medicare premium receipts, operating cash flows improved due to Medicare enrollment growth and improved earnings. Our Medicare Part D results related to both stand-alone PDP and Medicare Advantage offerings reflect provisions for net amounts payable to CMS of \$728.1 million for the 2006 contract year and net amounts receivable from CMS of \$37.9 million for the 2007 contract year under the risk corridor terms of our contracts with CMS. The risk corridor amounts generally are expected to be settled with CMS in the subsequent year during the third or fourth quarter. For example, the \$728.1 million risk corridor payable amount associated with the 2006 contract year is expected to be settled during the fourth quarter of 2007.

Comparisons of our operating cash flows also are impacted by changes in our working capital. The most significant drivers of changes in our working capital are typically the timing of receipts for premiums and administrative services fees and payments of medical expenses. We illustrate these changes with the following summary of receivables and medical and other expenses payable.

The detail of total net receivables was as follows at June 30, 2007 and December 31, 2006:

| | June 30, 2007 | December 31, 2006 | Change |
|---------------------------------|------------------|----------------------|------------------|
| | (in thousands) | | |
| TRICARE: | | | |
| Base receivable | \$499,407 | \$ 452,509 | \$ 46,898 |
| Change orders | 4,352 | 4,247 | 105 |
| TRICARE subtotal | 503,759 | 456,756 | 47,003 |
| Medicare | 124,168 | 143,875 | (19,707) |
| Commercial and other | 138,953 | 125,899 | 13,054 |
| Allowance for doubtful accounts | (69,327) | (45,589) | (23,738) |
| Total net receivables | <u>\$697,553</u> | <u>\$ 680,941</u> | <u>\$ 16,612</u> |

TRICARE base receivables consist of estimated amounts owed from the federal government for claims incurred including claims incurred but not reported, or IBNR, and underwriting fees. The claim reimbursement component of TRICARE base receivables is generally collected over a three to four month period. The \$46.9 million increase in base receivables primarily resulted from an increase in the underwriting fee receivables associated with the third option period.

Table of Contents

The \$19.7 million decrease in Medicare receivables as of June 30, 2007 as compared to December 31, 2006 primarily resulted from a decrease in receivables associated with CMS's risk adjustment model.

The \$23.7 million increase in the allowance for doubtful accounts resulted from the growth of the Medicare business.

The detail of medical and other expenses payable was as follows at June 30, 2007 and December 31, 2006:

| | June 30, 2007 | December 31, 2006 (in thousands) | Change |
|--|--------------------|--|------------------|
| IBNR (1) | \$1,882,042 | \$1,678,052 | \$203,990 |
| TRICARE claims payable (2) | 429,033 | 430,674 | (1,641) |
| Reported claims in process (3) | 122,225 | 98,033 | 24,192 |
| Other medical expenses payable (4) | 520,846 | 281,502 | 239,344 |
| Total medical and other expenses payable | <u>\$2,954,146</u> | <u>\$2,488,261</u> | <u>\$465,885</u> |

- (1) IBNR represents an estimate of medical expenses payable for claims incurred but not reported (IBNR) at the balance sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received (i.e. a shorter time span results in a lower IBNR).
- (2) TRICARE claims payable includes all claim activity associated with TRICARE, including IBNR and payables for sharing risk with the federal government for cost overruns.
- (3) Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling.
- (4) Other medical expenses payable includes capitation and pharmacy payables. The balance due to our pharmacy benefit administrator fluctuates due to bi-weekly payments and the month-end cutoff.

Medical and other expenses payable primarily increased during 2007 due to growth in Medicare membership, an increase in capitation payable, the timing of pharmacy payables, and to a lesser extent medical claims inflation.

Cash Flow from Investing Activities

We reinvested a portion of our operating cash flows in investment securities, primarily short-duration fixed income securities, totaling \$176.7 million in the 2007 period. Our ongoing capital expenditures primarily relate to our information technology initiatives and administrative facilities necessary for activities such as claims processing, billing and collections, medical utilization review, and customer service. Total capital expenditures, excluding acquisitions, were \$114.7 million in the 2007 period compared to \$82.0 million in the 2006 period. The increased spending in the 2007 period primarily resulted from the purchase of three medical centers in South Florida in the first quarter of 2007 for approximately \$20.4 million that were previously leased. During the 2007 period, we paid \$25.3 million to acquire DefenseWeb, net of \$1.6 million of cash acquired, and \$1.7 million to settle the purchase price contingencies associated with prior year acquisitions. During the 2006 period, we paid \$21.8 million to acquire CHA Health, net of \$43.5 million of cash acquired, and \$4.1 million to settle the purchase price contingencies associated with prior year acquisitions. Excluding acquisitions, we expect our total capital expenditures in 2007 to approximate \$220 million.

Cash Flow from Financing Activities

Net borrowings under our credit agreement decreased \$50 million in the 2007 period and \$200 million in the 2006 period. During the 2006 period, we issued \$500 million of 6.45% senior notes due June 1, 2016. Our net proceeds, reduced for the cost of the offering were \$494.7 million. We used a portion of these net proceeds from the offering for the repayment of the outstanding balance under our credit agreement.

Receipts from CMS associated with Medicare Part D subsidized claims for which we do not assume risk were \$259.4 million and \$308.6 million more than claim payments during the 2007 and 2006 periods, respectively.

The remainder of the cash provided by financing activities in the 2007 and 2006 periods resulted primarily from the change in the securities lending payable, proceeds from stock option exercises, the tax benefit from stock compensation, and the change in book overdraft.

Senior Notes

We previously issued in the public debt capital markets, \$300 million aggregate principal amount of 6.30% senior unsecured notes that mature on August 1, 2018 and \$500 million aggregate principal amount of 6.45% senior unsecured notes that mature on June 1, 2016. We have entered into interest rate swap agreements to exchange the fixed interest rate under these senior notes for a variable interest rate based on LIBOR.

[Table of Contents](#)

Credit Agreement

Our 5-year \$1.0 billion unsecured revolving credit agreement expires in July 2011. Under the credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either a fixed rate or floating rate based on LIBOR plus a spread. The spread, which varies depending on our credit ratings, ranges from 27 to 80 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 10 basis points, may fluctuate between 8 and 20 basis points, depending upon our credit ratings. In addition, a utilization fee of 10 basis points is payable for any day in which borrowings under the facility exceed 50% of the total \$1 billion commitment. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate basis, at our option.

The credit agreement contains customary restrictive and financial covenants as well as customary events of default, including financial covenants regarding the maintenance of a minimum level of net worth and a maximum leverage ratio. The terms of the credit agreement also include standard provisions related to conditions of borrowing, including a customary material adverse effect clause which could limit our ability to borrow additional funds. We have not experienced a material adverse effect and we know of no circumstances or events which would be reasonably likely to result in a material adverse effect. At this time, we do not believe the material adverse effect clause poses a material funding risk to us.

At June 30, 2007, we had \$400 million of borrowings under the credit agreement outstanding at an interest rate of 5.7%. In addition, we have outstanding letters of credit of \$1.8 million secured under the credit agreement. No amounts have ever been drawn on these letters of credit. As of June 30, 2007, we had \$598.2 million of remaining borrowing capacity under the credit agreement. We have other customary, arm's-length relationships, including financial advisory and banking, with some parties to the credit agreement.

Other Long-Term Borrowings

Other long-term borrowings of \$2.8 million at June 30, 2007 represent financing for the renovation of a building, bear interest at 2% per annum, are collateralized by the building, and are payable in various installments through 2014.

Shelf Registration

We have a universal shelf registration statement filed with the SEC which allows us to sell our debt or equity securities, from time to time, with the amount, price and terms to be determined at the time of the sale. The net proceeds from any future sales of our securities under the universal shelf registration may be used for our operations and for other general corporate purposes, including repayment or refinancing of borrowings, working capital, capital expenditures, investments, acquisitions, or the repurchase of our outstanding securities.

Liquidity Requirements

We believe our cash balances, investment securities, operating cash flows, access to debt and equity markets and borrowing capacity, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, to fund future expansion opportunities and capital expenditures in the foreseeable future, and to refinance debt as it matures.

Regulatory Requirements

Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, is limited based on the entity's level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required.

As of June 30, 2007, we maintained aggregate statutory capital and surplus of \$2,400.3 million in our state regulated subsidiaries. Each of these subsidiaries was in compliance with applicable statutory requirements which aggregated to \$1,736.1 million. Although the minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements can vary significantly at the state level. Given our anticipated continued premium growth in 2007, capital requirements will increase. We expect to fund these increased requirements with capital contributions from Humana Inc., our parent company, in the range of \$300 million to \$350 million for the full year 2007.

[Table of Contents](#)

Most states rely on risk-based capital requirements, or RBC, to define their required levels of equity discussed above. RBC is a model developed by the National Association of Insurance Commissioners to monitor an entity's solvency. This calculation indicates recommended minimum levels of required capital and surplus and signals regulatory measures should actual surplus fall below these recommended levels. If RBC were adopted by the remaining states and Puerto Rico at June 30, 2007, each of our subsidiaries would be in substantial compliance and we would have \$583.4 million of aggregate capital and surplus above any of the levels that require corrective action under RBC, or individual state requirements.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

No material changes have occurred in our exposures to market risk since the date of our Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

Item 4. Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, or CEO, our Chief Financial Officer, or CFO, and our principal accounting officer, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for the quarter ended June 30, 2007.

Based on our evaluation, our CEO, CFO and principal accounting officer concluded that our disclosure controls and procedures are effective, at a reasonable assurance level, in timely alerting them to material information required to be included in our periodic SEC reports.

There have been no significant changes in the Company's internal control over financial reporting that occurred during the Company's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. Other Information

Item 1: Legal Proceedings

For a description of the litigation and legal proceedings pending against us, see “Legal Proceedings” in Note 9 to the condensed consolidated financial statements beginning on page 10 of this Form 10-Q.

Item 1A. Risk Factors

The Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 as filed with the SEC on February 23, 2007 have not materially changed. Some of the risks which may be relevant to us could include:

- if the premiums we charge are insufficient to cover the cost of health care services delivered to our members, or if our medical expense trends are higher than the level contemplated in our premiums, our profitability could decline;
- if we do not design and price our products properly and competitively, our membership and profitability could decline;
- if we fail to effectively implement our operational and strategic initiatives, including our Medicare initiatives, our business could be materially adversely affected;
- if we fail to properly maintain the integrity of our data, to strategically implement new information systems, or to protect our proprietary rights to our systems, our business could be materially adversely affected;
- we are involved in various legal actions, which, if resolved unfavorably to us, could result in substantial monetary damages;
- as a government contractor, we are exposed to additional risks that could adversely affect our business or our willingness to participate in government health care programs;
- our industry is currently subject to substantial government regulation, which, along with possible increased governmental regulation or legislative reform, increases our costs of doing business and could adversely affect our profitability;
- future changes by Congress to government programs, particularly Medicare, which may affect our ability or willingness to participate in these programs;
- any failure to manage administrative costs could hamper profitability;
- any failure by us to manage acquisitions, and other significant transactions successfully could harm our financial results, business and prospects;
- if we fail to develop and maintain satisfactory relationships with the providers of care to our members, our business could be adversely affected;
- our recently implemented mail order pharmacy business subjects us to additional regulations in addition to those we face with our core health benefits businesses;
- our ability to obtain funds from our subsidiaries is restricted;
- downgrades in our debt ratings, should they occur, may adversely affect our business, financial condition and results of operations; and
- increased litigation and negative publicity could increase our cost of doing business.

This list of important factors is not intended to be exhaustive. A further list and description of some of these risks and uncertainties can be found in our reports filed with the SEC from time to time, including our annual reports on Form 10-K and quarterly reports on Form 10-Q. Any or all forward-looking statements we make may turn out to be wrong. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except to the extent otherwise required by federal securities laws, we do not undertake to publicly update or revise any forward-looking statements.

[Table of Contents](#)

Item 2: [Unregistered Sales of Equity Securities and Use of Proceeds](#)

None.

Item 3: [Defaults Upon Senior Securities](#)

None.

Item 4: [Submission of Matters to a Vote of Security Holders](#)

None.

Item 5: [Other Information](#)

None.

Item 6: [Exhibits](#)

12 Computation of ratio of earnings to fixed charges.

31.1 CEO certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.

31.2 CFO certification pursuant to Section 302 of Sarbanes–Oxley Act of 2002.

32 CEO and CFO certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes–Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HUMANA INC.
(Registrant)

Date: August 3, 2007

By: /s/ STEVEN E. MCCULLEY
Steven E. McCulley
Vice President and Controller
(Principal Accounting Officer)

Date: August 3, 2007

By: /s/ KATHLEEN PELLEGRINO
Kathleen Pellegrino
Acting General Counsel

Humana Inc.
Computation of Ratio of Earnings to Fixed Charges

| | For the six months ended June 30, 2007 | For the twelve months ended December 31, | | | | |
|---|--|--|------------------|------------------|------------------|------------------|
| | | 2006 | 2005 | 2004 | 2003 | 2002 |
| | | (Dollars in thousands) | | | | |
| Income before income taxes | \$ 451,811 | \$762,085 | \$402,880 | \$399,378 | \$336,213 | \$203,546 |
| Fixed charges | 53,913 | 98,045 | 66,434 | 49,246 | 40,972 | 44,349 |
| Total earnings | <u>\$ 505,724</u> | <u>\$860,130</u> | <u>\$469,314</u> | <u>\$448,624</u> | <u>\$377,185</u> | <u>\$247,895</u> |
| Interest charged to expense | \$ 33,984 | \$ 63,141 | \$ 39,315 | \$ 23,172 | \$ 17,367 | \$ 17,252 |
| One-third of rent expense | 19,929 | 34,904 | 27,119 | 26,074 | 23,605 | 27,097 |
| Total fixed charges | <u>\$ 53,913</u> | <u>\$ 98,045</u> | <u>\$ 66,434</u> | <u>\$ 49,246</u> | <u>\$ 40,972</u> | <u>\$ 44,349</u> |
| Ratio of earnings to fixed charges (1)(2) | <u>9.4x</u> | <u>8.8x</u> | <u>7.1x</u> | <u>9.1x</u> | <u>9.2x</u> | <u>5.6x</u> |

Notes

- (1) For the purposes of determining the ratio of earnings to fixed charges, earnings consist of income before income taxes and fixed charges. Fixed charges include gross interest expense, amortization of deferred financing expenses and an amount equivalent to interest included in rental charges. One-third of rental expense represents a reasonable approximation of the interest amount.
- (2) There are no shares of preferred stock outstanding.

CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, Michael B. McCallister, principal executive officer of Humana Inc., certify that:

1. I have reviewed this Quarterly Report of Humana Inc. (the "Company") on Form 10-Q for the period ending June 30, 2007;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2007

Signature: /s/ Michael B. McCallister

Michael B. McCallister
Principal Executive Officer

CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002

I, James H. Bloem, principal financial officer of Humana Inc., certify that:

1. I have reviewed this Quarterly Report of Humana Inc. (the "Company") on Form 10-Q for the period ending June 30, 2007;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2007

Signature: /s/ James H. Bloem
James H. Bloem
Principal Financial Officer

***CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002***

In connection with the Quarterly Report of Humana Inc. (the "Company") on Form 10-Q for the period ending June 30, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Humana Inc., that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Michael B. McCallister

Michael B. McCallister
Principal Executive Officer

August 3, 2007

/s/ James H. Bloem

James H. Bloem
Principal Financial Officer

August 3, 2007

A signed original of this written statement required by Section 906 has been provided to Humana Inc. and will be retained by Humana Inc. and furnished to the Securities and Exchange Commission or its staff upon request.